Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
14.08
-0.45 (-3.10%)
Apr 16, 2026, 4:00 PM EDT - Market closed
Adaptive Biotechnologies Revenue
In the year 2025, Adaptive Biotechnologies had annual revenue of $276.98M with 54.77% growth. Adaptive Biotechnologies had revenue of $71.68M in the quarter ending December 31, 2025, with 51.04% growth.
Revenue (ttm)
$276.98M
Revenue Growth
+54.77%
P/S Ratio
7.83
Revenue / Employee
$443,872
Employees
624
Market Cap
2.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.98M | 98.02M | 54.77% |
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Ultragenyx Pharmaceutical | 673.00M |
| Aurinia Pharmaceuticals | 283.06M |
| Stoke Therapeutics | 184.42M |
| Syndax Pharmaceuticals | 172.35M |
| Day One Biopharmaceuticals | 158.18M |
| Zymeworks | 105.97M |
| Nektar Therapeutics | 55.23M |
ADPT News
- 1 day ago - Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech - GeekWire
- 3 months ago - Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Reuters